Skip to main content
. 2018 Dec 10;9(24):4762–4773. doi: 10.7150/jca.25138

Figure 1.

Figure 1

Effect of combination of dasatinib with various HDAC inhibitors on cell proliferation of pancreatic cancer cells. Six human pancreatic cancer cell lines (SU8686, BxPc3, MiaPaCa2, Panc0203, Panc1, Panc1005) were treated with either single drug dasatinib, HDAC inhibitor (belinostat, panobinostat, vorinostat) or combination of both at various concentrations for 72h. Cell viability was measured (MTT assay); and data were normalized to controls without drug treatment. Das, dasatinib; Bel, belinostat; Pan, panobinostat; SAHA, vorinostat.